A detailed history of Rafferty Asset Management, LLC transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 45,840 shares of KRYS stock, worth $7.56 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
45,840
Previous 41,800 9.67%
Holding current value
$7.56 Million
Previous $7.68 Million 8.6%
% of portfolio
0.03%
Previous 0.03%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$174.7 - $213.66 $705,788 - $863,186
4,040 Added 9.67%
45,840 $8.34 Million
Q2 2024

Aug 13, 2024

SELL
$153.12 - $183.64 $1.77 Million - $2.12 Million
-11,567 Reduced 21.67%
41,800 $7.68 Million
Q1 2024

May 13, 2024

SELL
$108.01 - $179.35 $3.31 Million - $5.5 Million
-30,654 Reduced 36.48%
53,367 $9.5 Million
Q4 2023

Feb 13, 2024

BUY
$96.0 - $128.29 $1.17 Million - $1.57 Million
12,215 Added 17.01%
84,021 $10.4 Million
Q3 2023

Nov 13, 2023

BUY
$108.51 - $130.22 $2.02 Million - $2.43 Million
18,623 Added 35.02%
71,806 $8.33 Million
Q2 2023

Aug 11, 2023

SELL
$78.48 - $130.32 $654,601 - $1.09 Million
-8,341 Reduced 13.56%
53,183 $6.24 Million
Q1 2023

May 11, 2023

SELL
$72.39 - $84.27 $7,311 - $8,511
-101 Reduced 0.16%
61,524 $4.93 Million
Q4 2022

Feb 13, 2023

BUY
$63.14 - $79.9 $591,558 - $748,583
9,369 Added 17.93%
61,625 $4.88 Million
Q3 2022

Nov 14, 2022

BUY
$64.85 - $82.4 $1.24 Million - $1.57 Million
19,064 Added 57.44%
52,256 $3.64 Million
Q2 2022

Aug 12, 2022

SELL
$48.93 - $73.47 $1.31 Million - $1.97 Million
-26,820 Reduced 44.69%
33,192 $2.18 Million
Q1 2022

May 13, 2022

BUY
$51.99 - $72.11 $1.43 Million - $1.98 Million
27,519 Added 84.69%
60,012 $3.99 Million
Q4 2021

Feb 10, 2022

BUY
$39.81 - $88.24 $367,804 - $815,249
9,239 Added 39.73%
32,493 $2.27 Million
Q3 2021

Nov 10, 2021

BUY
$52.01 - $71.77 $46,392 - $64,018
892 Added 3.99%
23,254 $1.21 Million
Q2 2021

Aug 10, 2021

SELL
$62.14 - $81.82 $223,455 - $294,224
-3,596 Reduced 13.85%
22,362 $1.52 Million
Q1 2021

May 10, 2021

BUY
$59.42 - $85.46 $1.29 Million - $1.85 Million
21,665 Added 504.66%
25,958 $2 Million
Q4 2020

Feb 10, 2021

SELL
$40.64 - $61.38 $354,868 - $535,970
-8,732 Reduced 67.04%
4,293 $258,000
Q3 2020

Nov 13, 2020

BUY
$37.76 - $48.49 $200,128 - $256,997
5,300 Added 68.61%
13,025 $561,000
Q2 2020

Aug 07, 2020

BUY
$37.03 - $60.0 $286,056 - $463,500
7,725 New
7,725 $320,000
Q1 2020

May 15, 2020

SELL
$35.02 - $65.64 $438,520 - $821,944
-12,522 Closed
0 $0
Q4 2019

Feb 10, 2020

SELL
$33.17 - $65.23 $468,028 - $920,395
-14,110 Reduced 52.98%
12,522 $693,000
Q3 2019

Nov 14, 2019

BUY
$34.72 - $51.3 $924,663 - $1.37 Million
26,632 New
26,632 $925,000

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $4.23B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Rafferty Asset Management, LLC Portfolio

Follow Rafferty Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.